10th Neurodegenerative Drug Development Summit

Temas de la conferencia
With Biogen’s Aducanumab approval dramatically overhauling the regulatory landscape for neurodegenerative disease, the beta amyloid revival is in full swing with investment pouring in across multiple neurodegenerative diseases. With this, biopharma across the globe are racing to harness the exhilarating momentum of the past year and turbocharge their neurodegenerative disease drug development in 2022 and beyond.

Organizador profesional (PCO)
Hanson Wade

https://go.evvnt.com/961759-2?pid=4832

Ms. Stephanie Nketia